Cargando…

Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial

Management of nonalcoholic steatohepatitis (NASH) is a currently unmet clinical need. Digital therapeutics (DTx) is an emerging class of medicine that delivers evidence-based therapeutic interventions. This study was aimed at investigating the efficacy of DTx in patients with NASH. METHODS: We condu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Masaya, Akamatsu, Masatoshi, Shima, Toshihide, Ikegami, Tadashi, Yanase, Mikio, Mikami, Shintaro, Imamura, Jun, Nakatsuka, Takuma, Tateishi, Ryosuke, Yamauchi, Naoko, Ushiku, Tetsuo, Okanoue, Takeshi, Fujishiro, Mitsuhiro, Hida, Eisuke, Koike, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392885/ https://www.ncbi.nlm.nih.gov/pubmed/36656974 http://dx.doi.org/10.14309/ajg.0000000000002143

Ejemplares similares

Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis
por: Soeda, Kotaro, et al.
Publicado: (2023)

Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis
por: Kawamura, Satoshi, et al.
Publicado: (2022)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells
por: Yamauchi, Akihiro, et al.
Publicado: (2017)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
por: Lee, Jin Ha, et al.
Publicado: (2020)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

A case of a tiny neuroendocrine carcinoma in a large flat-elevated rectal tumor causing multiple liver metastases
por: Ohki, Daisuke, et al.
Publicado: (2022)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
por: Losekann, Alexandre, et al.
Publicado: (2015)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
por: Min-DeBartolo, Jessica, et al.
Publicado: (2019)

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH)
por: Hartimath, S. V., et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
por: dos Santos, João Paulo Margiotti, et al.
Publicado: (2022)

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
por: Sekhon, Anupamjeet Kaur, et al.
Publicado: (2021)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
por: Li, Xinzhi, et al.
Publicado: (2021)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
por: Igreja Sá, Ivone Cristina, et al.
Publicado: (2020)

Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma
por: Yamada, Tomoharu, et al.
Publicado: (2023)

Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern
por: Kado, Akira, et al.
Publicado: (2023)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH)
por: Erhardt, A, et al.
Publicado: (2011)

A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice
por: Majeed, Muhammed, et al.
Publicado: (2020)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
por: Hadefi, Alia, et al.
Publicado: (2021)

The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH)
por: Salvoza, Noel, et al.
Publicado: (2022)

A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis
por: Li, Xuecheng, et al.
Publicado: (2023)

The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion
por: Niikura, Ryota, et al.
Publicado: (2019)

Development and prognosis of hepatocellular carcinoma in patients with diabetes
por: Nakatsuka, Takuma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t1jdfnsp4t4bghenusrsjrtnv1